Oruka Therapeutics (ORKA) Non-Current Assets (2010 - 2026)
Oruka Therapeutics' quarterly Non-Current Assets came in at $109.2 million in Q1 2026, up 336.42% year-on-year from $25.0 million in Q1 2025, and down 24.54% quarter-over-quarter from $144.8 million in Q4 2025.
Oruka Therapeutics has reported Non-Current Assets for 17 years, with the latest figure at $109.2 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 336.42% year-over-year to $109.2 million; the trailing twelve-month figure through Mar 2026 stood at $433.5 million (up 855.99% YoY), and the FY2025 full-year result was $144.8 million, up 655.93% from the prior year.
- Non-Current Assets for Q1 2026 stood at $109.2 million, down from $144.8 million in the prior quarter.
- The five-year high for Non-Current Assets was $154.1 million in Q3 2025, with the low at $24000.0 in Q2 2024.
- Average Non-Current Assets over 5 years is $28.3 million, with a median of $446000.0 recorded in 2022.
- Year-over-year, Non-Current Assets plunged 92.68% in 2024 and surged 105758.33% in 2025.
- Tracing ORKA's Non-Current Assets over 5 years: stood at $386000.0 in 2022, then plunged by 30.31% to $269000.0 in 2023, then surged by 7018.96% to $19.2 million in 2024, then surged by 655.93% to $144.8 million in 2025, then fell by 24.54% to $109.2 million in 2026.
- The last three Non-Current Assets figures came in at $109.2 million (Q1 2026), $144.8 million (Q4 2025), and $154.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | 109.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109.23 Mn |
| Dec 31, 2025 | 144.76 Mn |
| Sep 30, 2025 | 154.09 Mn |
| Jun 30, 2025 | 25.41 Mn |
| Mar 31, 2025 | 25.03 Mn |
| Dec 31, 2024 | 19.15 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 24,000.00 |
| Mar 31, 2024 | 36,000.00 |
| Dec 31, 2023 | 269,000.00 |
| Sep 30, 2023 | 292,000.00 |
| Jun 30, 2023 | 328,000.00 |
| Mar 31, 2023 | 357,000.00 |
| Dec 31, 2022 | 386,000.00 |
| Sep 30, 2022 | 415,000.00 |
| Jun 30, 2022 | 446,000.00 |
| Mar 31, 2022 | 475,000.00 |
| Dec 31, 2021 | 503,000.00 |
| Sep 30, 2021 | 526,000.00 |
| Jun 30, 2021 | 545,000.00 |
| Mar 31, 2021 | 453,000.00 |
| Dec 31, 2020 | 461,000.00 |
| Sep 30, 2020 | 46,000.00 |
| Jun 30, 2020 | 60,000.00 |
| Mar 31, 2020 | 83,000.00 |
| Dec 31, 2019 | 56,000.00 |
| Sep 30, 2019 | 45,000.00 |
| Jun 30, 2019 | 65,000.00 |
| Mar 31, 2019 | 87,000.00 |
| Dec 31, 2018 | 48,000.00 |
| Sep 30, 2018 | 53,000.00 |
| Jun 30, 2018 | 57,000.00 |
| Mar 31, 2018 | 61,000.00 |
| Dec 31, 2017 | 66,000.00 |
| Sep 30, 2017 | 545,000.00 |
| Jun 30, 2017 | 641,000.00 |
| Mar 31, 2017 | 735,000.00 |
| Dec 31, 2016 | 3.18 Mn |
| Sep 30, 2016 | 4.89 Mn |
| Jun 30, 2016 | 5.90 Mn |
| Mar 31, 2016 | 5.91 Mn |
| Dec 31, 2015 | 658,000.00 |
| Sep 30, 2015 | 710,000.00 |
| Jun 30, 2015 | 788,000.00 |
| Mar 31, 2015 | 587,000.00 |
| Dec 31, 2014 | 644,000.00 |
| Sep 30, 2014 | 574,000.00 |
| Jun 30, 2014 | 860,000.00 |
| Mar 31, 2014 | 854,000.00 |
| Dec 31, 2013 | 159,000.00 |
| Sep 30, 2013 | 127,000.00 |
| Jun 30, 2013 | 125,000.00 |
| Mar 31, 2013 | 146,000.00 |
| Dec 31, 2012 | 167,000.00 |
| Sep 30, 2012 | 197,000.00 |
| Jun 30, 2012 | 226,000.00 |
| Mar 31, 2012 | 256,000.00 |
| Dec 31, 2011 | 290,000.00 |
| Sep 30, 2011 | 410,000.00 |
| Jun 30, 2011 | 754,000.00 |
| Dec 31, 2010 | 994,000.00 |